Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
13F holders, Q2 2025
Institutional positions in Cidara Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +63 vs. Q1 2025
- Shares held
- 25.9M
- +16.4M (+171.1%) vs. Q1 2025
- Total value
- $1.26B
- +$1.06B (+513.3%) vs. Q1 2025
- New holders
- 71
- 29 more added
- Sold out
- 8
- 6 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 255 | $7.36B |
| Q3 2025 | 173 | $3.11B |
| Q2 2025 | 109 | $1.26B |
| Q1 2025 | 46 | $205.9M |
| Q4 2024 | 40 | $183.6M |
| Q3 2024 | 27 | $35.6M |
| Q2 2024 | 26 | $16.9M |
| Q1 2024 | 50 | $20.3M |
| Q4 2023 | 51 | $18.4M |
| Q3 2023 | 52 | $22.7M |
| Q2 2023 | 52 | $29.7M |
| Q1 2023 | 54 | $34.4M |
| Q4 2022 | 42 | $20.2M |
| Q3 2022 | 42 | $17.1M |
| Q2 2022 | 46 | $13.3M |
| Q1 2022 | 44 | $25.2M |
| Q4 2021 | 53 | $39.5M |
| Q3 2021 | 50 | $42.1M |
| Q2 2021 | 55 | $40.5M |
| Q1 2021 | 62 | $56.6M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Cidara Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 966,705 | $47.1M | 0.00% | +457,129+89.7% | Added |
| TCG Crossover Management, LLC | 1,005,901 | $49.0M | 5.60% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,100,000 | $53.6M | 0.09% | +110,000+11.1% | Added |
| BlackRock, Inc. | 1,107,668 | $54.0M | 0.00% | +1,054,772+1,994.0% | Added |
| Commodore Capital LP | 1,175,000 | $57.2M | 4.04% | +1,175,000 | New |
| Vivo Capital, LLC | 1,311,425 | $63.9M | 6.54% | +627,149+91.7% | Added |
| Point72 Asset Management, L.P. | 1,527,930 | $74.4M | 0.18% | +1,414,075+1,242.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,500,680 | $121.8M | 15.24% | +1,797,600+255.7% | Added |
| Ra Capital Management, L.P. | 3,365,523 | $163.9M | 2.76% | +2,272,727+208.0% | Added |
| Checkpoint Capital L.P. | 0 | $0 | 0.00% | −104,380−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −63,580−100.0% | Sold out |
| 5AM Venture Management, LLC | 0 | $0 | 0.00% | −56,725−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −27,849−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −19,300−100.0% | Sold out |
| Alethea Capital Management, LLC | 0 | $0 | 0.00% | −14,311−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −1,552−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −469−100.0% | Sold out |